Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Michael Pennock,Balazs Halmos,William Bodner,Haiying Cheng,Rasim Gucalp,Nitin Ohri

Clinical and Translational Radiation Oncology（2023）

引用 0|浏览19

暂无评分

摘要

•Many NSCLC patients do not finish the recommended one year of adjuvant durvalumab.•Cardiac irradiation extent was associated with early durvalumab discontinuation.•Early durvalumab discontinuation was associated with inferior clinical outcomes.•Extent of cardiac irradiation may predict inferior clinical outcomes.•Reducing cardiac irradiation is crucial for NSCLC treated with CRT & immunotherapy.

查看译文

关键词

cell lung cancer,lung cancer,durvalumab,chemoradiotherapy,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要